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Abstract
Background: This study reports on the use of whole exome sequencing (WES) to diagnose children with inborn
errors of metabolism and other disorders in United Arab Emirates.
Methods: From January 2012 to December 2014, 85 patients (46 % females) were seen in the metabolic center at
Tawam Hospital (Abu Dhabi) and WES testing was requested because definitive diagnoses were not reached by
conventional methods.
Results: Eighty (93 %) patients were <18 years old and 44 (52 %) were <5 years. Sixty-eight (80 %) patients had
neurologic abnormalities. WES facilitated rapid diagnosis in 50 % of the patients, especially those with
mitochondrial disorders. Yet, in most cases extensive investigation was required after the results were available.
Most patients with confirmed molecular diagnoses had autosomal recessive disorders and were homozygous for
the rare alleles. Most patients with autosomal dominant disorders and all patients with X-linked disorders had de
novo mutations. WES results were negative (no pathogenic variants related to patient phenotype were identified) in
six patients and incorrect in two patients. One patient had a reported “deleterious” hemizygous mutation in
SLC35A2, c.617_620del (p.Q206fs), suggesting ‘congenital disorder of glycosylation, TYPE IIm’, but glycosylation
studies were normal and healthy brothers had the same mutation. Another patient had “pathogenic” mutation in
MCCC2, c.1015G > A (p.V339M), but urine organic acids was normal. WES confirmed inborn errors of metabolism
(five mitochondrial diseases, three lysosomal storage diseases, and six other disorders) in 14 patients and genetic
disorders (14 neurological diseases and three non-neurological diseases) in 17 patients. Variants of unknown
significance were identified in 48 patients; 12 had “confirmed pathologic variants”and 12 had “likely pathologic
variants”, based on consistent phenotypes, biochemical/ segregation studies, or reported pathogenicity. In 24
patients, the variants were inconsistent with phenotypes or biochemical/ familial studies.
Conclusions: Although WES provided molecular diagnoses, the results required careful interpretations and many
patients required additional investigations. This tool is useful when conventional diagnostic methods fail. Staff
competence in obtaining consent/ permission, interpreting the findings, and providing the proper counseling are
essential before incorporating this technology into routine clinical practices.
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Background
Emirati people (citizens of United Arab Emirates, UAE)
have diverse ethnicities that include lineages from the
Arabian Peninsula, Persia, Baluchistan, and East Africa.
The culture is primarily tribal and encourages intra-
tribal (consanguineous) marriages [1]. Thus, “founder”
mutations are prevalent, which markedly increase the
frequency of autosomal recessive disorders [2]. Consist-
ently, the prevalence of inborn errors of metabolism
(IEM) in the region is high (about 1 in 1,329) [1]. Gen-
etic disorders are also exceptionally common [3].
Diagnosing IEM is often challenging due to their gen-
etic heterogeneity and atypical or overlapping pheno-
types. Using clinical assessments and conventional
investigations (having an estimated cost of about
$25,000 per patient), the rate of molecular diagnosis in
these patients is usually less than 50 % [4]. In these fam-
ilies, the lack of a diagnosis poses significant conse-
quences, such as patients missing treatments and failure
by medical staff to provide proper counseling and
guidance.
The relatively new term “exome” refers to all exons in the
human genome. The term “exons” refers to the ~180,000
genomic sequences, which transcribe and remain in the
mature RNA. Exome constitutes only 3 % of the human
genome and represents the ~22,000 protein-coding genes,
mutations of which are responsible for about 85 % of our
significant clinical diseases [5–7]. Therefore, sequencing of
the exome is thought to be an efficient method of analyzing
a patient's DNA to discover the genetic cause of disease.
WES is especially efficient in detecting rare mutations in
autosomal recessive diseases in consanguineous families.
The recently introduced WES technology offers an ad-
junctive analytical tool to locus-specific and gene-panel
testing for patients with wide-spectrum phenotypes. This
study describes diagnostic rate, advantages, and limita-
tions of WES in the UAE.
Methods
This study was approved by Al-Ain Medical Human
Research Ethics Committee (protocol number 10/09).
Between January 2012 and December 2014, at Tawam
Hospital (Al Ain, Abu Dhabi), 85 WES studies were
requested. The risks and benefits of the test were ex-
plained to families and patients and written informed
consent/ permission was obtained. WES was requested
because of atypical phenotypes, overlapping features, or
negative biochemical studies.
Blood (5 mL in EDTA-Vacutainer) was obtained from
patients, parents and affected family members (when
applicable). Extracted DNA was shipped to Whole Gen-
ome Laboratory (WGL) of Baylor College of Medicine
(Houston, TX, USA). Single WES was performed at
WGL as previously reported [6]. Briefly, genomic DNA
from patients was fragmented by sonication. The frag-
ments were ligated to illumina multiplexing paired-end
adapters, amplified by polymerase chain-reaction assay,
and hybridized to biotin-labeled VCRome (at 47 °C for
64–72 h). Paired-end sequencing was performed on Illu-
minaHiSeq 2000 platform. The mean coverage of the
exome was 100 – 120X; and 95 % of the exome was cov-
ered at >20X coverage. The output data from Illumina-
HiSeqwere converted from bcl file to FastQ file by
Illumina Consensus Assessment of Sequence and Vari-
ation Software and mapped by Burrows-Wheeler Aligner
(BWA) program. Variants were filtered using stringen-
cies of minor allele frequencies and mutation databases
and disease specific databases. The results (with disease
phenotype) were interpreted by molecular laboratory
and medical directors certified by American board of
Medical Genetics. Variant annotation and filtering were
performed using Atlas-SNP and Atlas-indel.16, in
addition to CASSANDRA software. Variants with a
minor allele frequency of less than 5 % (according to ei-
ther the 1000 Genomes Project18 or the ESP5400 data
of the National Heart, Lung, and Blood Institute GO Ex-
ome Sequencing Project [http://evs.gs.washington.edu/
EVS]) were retained. Variants were interpreted according
to American College of Medical Genetics guidelines and
patient phenotypes. Variants related to patient pheno-
types were confirmed by Sanger sequencing for the pa-
tients, parents and affected relative if applicable. The
interpretation of genes related to the patient’s clinical
phenotype was based on the clinical information of the
patient. WES reports included also In silico-predictions
for non-synonymous (missense) changes by SIFT and
PolyPhen-2 [6]. Table 1 lists variants of unknown signifi-
cance that confirmed the clinical disorder after further
investigations. Tables 2, 3 list pathogenic mutations that
directly confirmed the clinical disorder without a need
for further investigation.
Results
Eighty-five patients (46 % females) had WES testing.
WES results were divided into the following categories:
[1] Variants of unknown significance, which were con-
firmed pathogenic (12 patients, Group A) or likely patho-
genic (12 patients, Group B) based on consistent
phenotypes, biochemical findings, familial (segregation)
studies, or reported pathogenicity (Table 1); [2] WES diag-
nosis of IEM (14 patients, Table 2); [3] WES diagnosis of
genetic diseases (17 patients, Table 3); [4] Variants of un-
known significance, which were inconsistent with patients’
phenotypes or biochemical/ familial (segregation) studies
(24 patients); and [5] No pathogenic variants related to
patient phenotype were identified (six patients).
Patients who had variants of unknown significance
were investigated using biochemical tests, familial
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Table 1 Variants of unknown significance, which were confirmed pathogenic or likely pathogenic
Group A: Confirmed pathogenic (n = 12) a
Genes (Isoforms) Variants (PMID) Diagnoses (MIM) Comments
Autosomal Recessive Inheritance
TALDO1 (NM_006755) c.574C > T (p.A192C) (23315216) Transaldolase deficiency (606003) Elevated level of polyol in urine. Affected family members had
the same variant.
ETHE1 (NM_014297) c.488G > A (p.R163Q) b(14732903) EE (602473) Urine organic acid and acylglycine profiles were consistent with
ethylmalonic encepathopathy.
FBXL4 c c.1304G > T (p.R435L) b(23993193) MTDPS13(615471) Affected sibling had the same variant and healthy siblings were
negative.
DGUOK (NM_080916) c.763_765del (p.D255del) b MTDPS3 (251880) Affected sibling had the same variant.
PEX16 (NM_004813) c.859C > T (p.R287C) b PBD8B (614877) Elevated level of very long chain fatty acids, low C26 beta-oxidation
in plasma and fibroblasts. Fibroblasts showed enlarged peroxisomes.
Affected sibling had the same variant.
HEXB (NM_000521) c.272G > C (p.C91S) b Sandhoff disease (268800) Low serum hexosaminidase activity. A pathologic variant in MCCC2
[c.1015G > A (p.V339M)] was also found, but urine organic acids
were normal (PMID: 11181649).
ATP8B1 (NM_005603) c.379C > G (p.L127V)b BRIC (243300) Affected sibling had the same variant and healthy siblings were
negative.
MTPAP (NM_018109) c.1468G > T (p.V490L) SPAX4 (613672) Developmental delay and regression at 8 months of age, central
hypotonia, short stature, failure to thrive, cerebellar atrophy,
absence-like episodes, and hip dislocation. Affected sibling had
the same variant. Parents were heterozygous.
RNASEH2C (NM_032193) c.205C>T (p.R69W) (16845400) AGS3 (610329) Global developmental delay, central hypotonia, peripheral
hypertonia, opisthotonus, microcephaly, failure to thrive, diffuse
white matter hyperintensity, cortical brain atrophy, and dilated
ventricles. WES also reported homozygous variant in CDK5RAP2
[c.412G > A (p.G138S); an unaffected sibling was homozygous
for the same variant] and pathogenic heterozygous mutation
in BUB1B [c.2441G > A (p.R814H)].
Autosomal Dominant Inheritance
FOXG1 c.1397G > A (p.G466E) b Rett (613454) Developmental regression, hypotonia, failure to thrive.
ANK2 (NM_001148) c.1135C > T (p.R379C) Long QT (600919) Two siblings died of cardiac arrest; affected sibling had the
same variant. Parents were heterozygous, but their phenotype
was not investigated.
X-Linked Inheritance
CDKL5 (NM_003159) c.593G=/>A (p.G198D) EIEE2 (300672) Global developmental delay and regression, intellectual disability,















Table 1 Variants of unknown significance, which were confirmed pathogenic or likely pathogenic (Continued)
Group B: Likely pathogenic (n = 12) a
Autosomal Recessive Inheritance
SLC4A4 (NM_000334) c.2230G > A (p.A744T) RTA, proximal (604278) Severe RTA and ocular hypertension. Parents were heterozygous.
G6PC (NM_000151) c.352G > C (p.A118P) (24980439) GSD1A (232200) Hypoglycemia, hepatosplenomegaly, ↑lactate, left ventricular
hypertrophy, and family history of cardiomyopathy.
MPDZ (NM_003829) c.[394G>A]; [1744C>G]
p.[G132S); [L582V]
HYC2 (615219) Communicating hydrocephaly.
TTN (NM_133378) c.[9160 G > C;68120 A > G]; [74633C >
T] p.[E3054;Y22707C];[A24878V]
CMD1G (604145 Mother was asymptomatic with the heterozygous c.9160 G > C
and c.68120 A > G. Father was heterozygous for c.74633C > T.
MIPEP (NM_005932) c.1027A > G (p.K343E) MIPEP (602241) Developmental delay, hypotonia, dysmorphism, microcephaly,
vision loss, and atrial septum defect.
ALG9 (NM_024740) c.694G > C (p.A232P) CDG1L (608776) Patient had global developmental delay and regression, central
and peripheral hypertonia, seizures, macrocephaly, brain atrophy,
thin corpus callosum, and cysts in the white matter. WES also
reported homozygous variants in NDUFV3 [c.552dup (p.L185fs)]
and in KANK1 [c.1079G > A (p.S360N)].
GLRA1 (NM_000171) c.1214G > A (p.R405Q) HKPX1 (149400) Global developmental delay, hypotonia then hypertonia, seizures,
repetitive hand movements, startle reflex to tactile and sound,
dysmorphic features (elongated face, big prominent ears), tall
habitus, squint, scoliosis, and precious puberty. WES also reported
homozygous variants in TTC37 [c.1828A > G (p.S610G)] and in
CHD8 [c.1952G > A (p.R651Q)].
PLA2G6 (UC003aux.1) c.154G > A (p.V52M) NBIA2B (610217) Developmental regression, hypertonia, failure to thrive, scoliosis,
and skin anomalies. Brain MRI findings were consistent with
NBIA2B. Cousin with spina bifida and hydrocephalus. WES also
reported homozygous variant in ACOX1 [c.1165A > G (p.I1389V)]
and compound heterozygous variant in SACS [c.2143C > A
(p.P715T) and c.5732C > A (p.T1911M)].
Autosomal Dominant Inheritance
ABCB6 (NM_005689) c.[4G > A; 904C > G] p.[V2M;L302V] MCOPCB7 (614497) Autism, subtle microphthalmia, and repetitive hand movements.
WES also identified a heterozygous variant in CHD7 [c.5689G > A
(p.E1897K)]. (CHARGE, MIM: 214800) Father had small eyes and was
heterozygous for both changes.
ITPR1 (NM_002222) c.3758 T > A (p.I1253N) SCA15 (606658) Ataxia and cerebellar atrophy without deafness. WES also reported
a variant in MYH14 [c.1126G > T (p.G376C)]. (PMID: 15015131,
MIM: 600652)
CHRNB1 (NM_000747) c.865G > A (p.V289M) (8872460) CMS2A (616313) Delayed motor milestone, hypotonia, pulmonary hypertension,
seizures, and autistic features. Nerve conductive study was normal.
















Table 1 Variants of unknown significance, which were confirmed pathogenic or likely pathogenic (Continued)
KIF5C (NM_004522) c.404A > G (p.Y135C) Cortical dysplasia, complex, with
other brain malformations 2 (615282)
The disease is autosomal dominant. All family members were
negative for the variant. WES also reported a variant in NRXN1
[c.1835A > G (p.D612G)]. Parents and one sibling were
heterozygous (MIM: 614325).
a Group A was based on consistent phenotypes, biochemical findings, familial (segregation) studies, or reported pathogenicity
b Novel mutations
Mutations in bold were de novo
All mutations were homozygous, except those in Italics which were heterozygous
c WES was done in Netherland
PMID PubMed Identifier, MIM Mendelian Inheritance in Man, EE encephalopathy, ethylmalonic, MTDPS13 mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), MTDPS3 mitochondrial DNA depletion
syndrome 3 (hepatocerebral type), PBD8B peroxisome biogenesis disorder 8B, BRIC cholestasis, benign recurrent intrahepatic, SPAX4 spastic ataxia 4, autosomal recessive, AGS3 aicardi-goutieres syndrome 3, Long QT
cardiac arrhythmia, ankyrin-B-related, EIEE2 epileptic encephalopathy, early infantile
a Group B was based on consistent phenotypes or previously reported probable pathogenicity
All mutations were homozygous, except those in Italics which were heterozygous
RTA, renal tubular acidosis, GSD1A glycogen storage disease Ia, HYC2 hydrocephalus, nonsyndromic, autosomal recessive 2, CRS3 craniosynostosis 3, CMD1G cardiomyopathy, dilated, 1G, MIPEP mitochondrial
intermediate peptidase, CHARGE CHARGE syndrome, CDG1L congenital disorder of glycosylation, type lL, HKPX1 hyperekplexia, hereditary 1, NBIA2B neurodegeneration with brain iron accumulation 2b, MCOPCB7















Table 2 Confirmed IEM by WES. n = 14
Gene (Isoform) Variants (PMID) Diagnosis (MIM) Comments
Mitochondrial inheritance
tRNA Ala m.5591G > Ab (16476954) MTTA (590000) Failure to thrive, ptosis, myopathy, normal mitochondrial studies on muscle biopsy.
ND5 m.13513G > A (p.D393N)b (12509858) MTND5 (516005) Developmental regression, dysmorphic features, esotropia, chorioretinal atrophy,
seizure, left ventricular hypertrophy, renal insufficiency, brain image suggestive of
Leigh syndrome.
X-Linked inheritance
PDHA1 (NM_000284) c.787C > G (p.R263G) (1508605) PDHAD (312170) Brain image suggestive of Leigh syndrome; low complex II (succinate dehydrogenase)
activity in the fibroblasts. Two heterozygous (‘cis’ configuration) novel missense variants,
c.321C > G (p.1107 M) and c.338A > T (p.N113I), in SDHA were found in patient and father.
Autosomal recessive inheritance
FBXL4 (NM_012160) c.1067delG (p.G356fs) (23993194) MTDPS13 (615471) Developmental regression, hypotonia, failure to thrive, microcephaly, lactic acidosis, normal
fibroblast mitochondrial studies. Three siblings died in infancy.
C10orf2 (NM_021830) c.1198C > T (p.R400C) (21364701) MTDPS7 (271245) Developmental regression, hearing loss, scoliosis, reduced activities of complexes I & IV in
myocytes; normal activities in fibroblasts. Two cousins with Leigh disease.
MTHFR (NM_005957) c.1596C > G(p.Y532) (a) MTHFRD (236250) Progressive encephalopathy, seizure, cerebral venous thrombosis, gangrenous like bullous
formation in the leg, congenital heart disease, ↑homocysteine, ↓methionine.
PYCR2 (NM_013328) c.28C > T(p.Q10X) (a) HLD10 (616420) Developmental regression, failure to thrive, seizure, microcephaly, severe demyelination,
thin corpus callosum.
c.796C > T(p.R266X) (a) Developmental delay, hypotonia, failure to thrive, microcephaly, thin corpus callosum,
delayed myelination.
HEXA (NM_000520) c.2 T > C Tay-Sachs (268800) Developmental regression, failure to thrive, seizure disorders, dystonia, feeding difficulties
constipation. Diagnosis confirmed by enzyme analysis.
HEXB (NM_000521) c.826_829del (p.E276fs) Sandhoff (268800) Developmental regression, failure to thrive, feeding difficulties, seizure, and vision loss.
SUMF1 (NM_182760) c.691dupT (p.W231fs) c.689A > G (p.E230ZG) MSD (272200) Developmental delay, seizure, hepatomegaly, delayed myelination, ↑urine sulfatide, ↑urine
heparan sulphate.
UROC1 (NM_144639) c.855G > A (p.W285X) (a) UROCD (276880) Intellectual disabilities, attention deficit and hyperactivity disorder, hyperextensible joints,
↑imidazole propionate.
TBX19 (NM_005149) c.604-1G > C (a) IAD (201400) Intellectual disabilities, congenital hypothyroidism, two sisters died in infancy with
hypoglycemia.
HSD3B7 (NM_025193) c.45_46del (p.G17fs) (12679481) CBAS1 (607765) Neonatal cholestasis, hepatosplenomegaly, hypotonia, failure to thrive.
(a) Novel mutation; (b) heteroplasmic mutations (56-59 %). Mutations in bold are de novo, All mutations are homozygous, except those in Italics, which are heterozygous. PMID PubMed Identifier, MIM Mendelian
Inheritance in Man, MTTA transfer RNA, mitochondrial, alanine, MTND5 complex I, subunit ND5, PDHAD pyruvate dehydrogenase e1-alpha deficiency, SDHA succinate dehydrogenase complex, subunit A, flavoprotein,
MTDPS13 mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), MTDPS7 mitochondrial DNA depletion syndrome 7 (hepatocerebral type); MTHFRD methylenetetrahydrofolate reductase deficiency,















Table 3 Confirmed genetic diseases by WES, n = 17
Gene (Isoform) Variants (PMID) Diagnosis (MIM) Comments
X-Linked Inheritance
PAK3 (NM_002578) c.1279 T > C (p.Y427H) MRX30 (300558) Intellectual disabilities, macrocephaly, obesity.
Autosomal Dominant Inheritance
BRAF (NM_004333) c.1914 T > G (p.D638E) (19206169) CFC1 (115150) Cortical blindness, seizures, stridor, constipation
and developmental delay.
DYNC1H1 (NM_001376) c.10973G > A (p.G3658E) MRD13 (614563) Developmental regression, seizure, microcephaly,
cataract, lissencephaly, pachygyria, grey matter
heterotopia, hypoplasia of the corpus callosum.
ARID1B (NM_020732) c.4870C > T (p.R1624X)(a) Coffin-Siris (135900) Mucopolysaccharidosis suspected clinically.
ARID1B (NM_020732) c.3689 + 1G > C Coffin-Siris (135900) Global developmental delay, failure to thrive,
acute encephalopathy with hypoglycemia and
metabolic acidosis.
MYBPC3 (NM_000256) c.776delinsTT (p.A259fs) CMD1MM (615396) Dilated cardiomyopathy.
Autosomal Recessive Inheritance
SNX10 (NM_001199835) c.112-1G > C OPTB8 (615085) Central hypotonia, optic atrophy, osteopetrosis,
pulmonary hypoplasia, hyperpigmented macules.
TRAPPC11 (NM_199053) c.2938G > A (p.G980R) (23830518) LGMD2S (615356) Developmental delay, head nodding, hypotonia,
↑CPK, ↑plasma phenylalanine, normal CSF
neurotransmitters. Homozygous c.362 T > C
(p.I121T) variant in COQ9 (normal muscle
coenzyme Q10 activity).
PCSK1 (NM_000439) c.1312C > T (p.R438X) Proprotein convertase 1/3 deficiency (600955) Brain hemorrhage, congenital diarrhea.
ERCC5 (NM_000123) c.205C > T (p.R69X)(a) Cockayne (278780) Hypotonia, developmental delay and seizure.
Clinically suspected to have MLCD.
AHI1 (NM_017651) c.1051C > T (p.R351X) (15322546) Joubert syndrome-3 (608629) Intellectual disability, hypotonia, repetitive hand
movements, brain atrophy.
PRX (NM_181882) c.1090C > T (p.R364X) (21741241) Dejerine-Sottas (145900) Abnormal gait, hearing loss, loss of dexterity in
hands, scoliosis.
TREX1 (NM_003629) c.341G > A (p.R114H) (21270825) RVCL (192315) Cognitive impairment, hypotonia, joint
contracture, glaucoma, brain atrophy, sibling
died with the same features.
DOK7 (NM_173660) c.1124_1127dup (p.A378fs) & c.1457dup (p.A487fs) (16917026) Myasthenia, limb-girdle (254300) Hypotonia, myopathic changes in proximal muscles.
ADD3 (NM_016824) c.1100G > A (p.G367D) (23836506) Adducin-gamma (601568) Developmental delay, central hypotonia and
peripheral spasticity, cortical brain atrophy,















Table 3 Confirmed genetic diseases by WES, n = 17 (Continued)
RECQL4 (NM_004260) c.1000G > T (p.E334X)(a) RTS (268400) Premature, intrauterine growth retardation,
dry skin, clinically suspected to have MOPD2.
IKBKB (NM_001556) c.849G > A (p.W283X)(a) IMD15 (615592) Failure to thrive, recurrent infections, two sibling
died with the same presentation.
(a) Novel mutation. All mutations are homozygous, except those in Italics which are heterozygous. Variants in bold are de novo pathologic mutations. PMID,PubMed Identifier, MIM Mendelian Inheritance in Man, MRX30
mental retardation, X-linked 30, CFC1 cardiofaciocutaneous syndrome 1, MRD13 mental retardation, autosomal dominant 13, CMD1MM cardiomyopathy, dilated, 1MM; OPTB8 osteopetrosis, autosomal recessive 8;
LGMD2S muscular dystrophy, limb-girdle, type 2S, MLCD microcephaly-lymphedema chorioretinal dysplasia syndrome, RVCL vasculopathy, retinal, with cerebral leukodystrophy; isolated, RTS Rothmund-Thomson















(segregation) studies, and a review of the literature. Pa-
tients with consistent phenotypes, biochemical findings,
familial (segregation) studies, or reported pathogenicity
were considered “confirmed pathogenic” (Table 1A). Pa-
tients with consistent phenotypes or previously reported
probable pathogenicity were considered “likely patho-
genic” (Table 1B). The 24 patients who had ‘variants of
unknown significance’ that were inconsistent with their
phenotypes or biochemical/ familial (segregation) studies
were not included in this report.
A. Patients’ demographics
Eighty of the 85 (93 %) patients were younger than
18 years and 44 (52 %) were younger than 5 years. Sixty-
eight (80 %) patients had neurologic abnormalities. Pa-
tients had appropriate metabolic and genetic investiga-
tions (e.g., metabolic screening, microarray analysis, skin/
muscle biopsy, biochemical studies, and DNA testing) be-
fore WES testing. For most of patients, both parents DNA
were tested. The cost of WES was billed to insurance
companies in the UAE.
B. Molecular diagnoses
Fourteen (16 %) patients had IEM (Table 2), 17 (20 %)
had genetic syndromes (Table 3), 12 (14 %) had variants
of unknown significance confirmed to be pathogenic
(Table 1A), and 12 (14 %) had variants of unknown sig-
nificance likely to be pathogenic (Table 1B). Therefore,
WES information was clinically useful in 55 (65 %)
patients and diagnostic in 43 (50 %) patients.
Forty-one (75 %) of the 55 patients had consanguin-
eous families. All patients with autosomal recessive dis-
eases had consanguineous families (Tables 1–3); except
the patient with MTHFR mutation and the patient with
TBX19 mutation (Table 2) who had families of the same
tribe/ region; the patient with compound heterozygous
mutations in MPDZ (Table 1) and the patients with
PCSK1, AHI1, and DOCK7 mutations (Table 3). The pa-
tients with autosomal dominant mutation in CHRNB1
and FOXG1 (Table 1), the patient with mitochondrial
mutation in tRNA Ala (Table 2), and the patient with
X-linked mutation in PDHA1 (Table 2) had non-
consanguineous families. In Table 3, the patients with
X-linked or autosomal dominant conditions had non-
consanguineous families, except for the patient with
MYBPC3 mutations.
One hundred twenty-eight variants were identified.
Forty-four (34 %) variants were pathologic. Twenty
(15 %) of these variants were previously reported and 24
(19 %) were novel.
C. Autosomal dominant mutations
Eleven (13 %) patients had autosomal dominant disor-
ders. Five patients had truncating or missense mutations
which were previously reported. Three of these muta-
tions were de novo (Table 3). Six patients had autosomal
dominant (Table 1); three were de novo variant, one was
inherited from symptomatic parent, and two were inher-
ited from parents of unknown phenotype.
D. Autosomal recessive mutations
Forty (47 %) patients had autosomal recessive diseases.
Thirty-five patients had homozygous variants and five
patients had compound heterozygous variants. Eleven
pathogenic mutations involved inborn errors of metabol-
ism (Table 2). Five of these mutations were novel,
including a compound heterozygous mutation (Table 2).
Eleven pathogenic homozygous mutations involved gen-
etic syndromes (Table 3). Five of these mutations were
previously reported and six were novel (Table 3).
Of the reported variants of unknown significance, nine
were confirmed pathogenic homozygous mutations on
further testing, six of which were novel (Table 1A).
Seven of these disorders were IEM (Table 1A). In
addition, six homozygous and three compound heterozy-
gous variants were likely pathogenic; only one of these
variants was previously reported (Table 1B).
E. X-linked mutations
The three patients with X-linked disorders had de novo
mutations; one had pyruvate dehydrogenase e1-alpha
deficiency (Table 2) and one had mental retardation, X-
linked 30 (Table 3). The patient with epileptic encephal-
opathy, early infantile had mosaic de novo variant
(Table 1A).
F. Mitochondrial mutations
Two female patients had known pathogenic mutations.
The patient with Leigh disease had 56 % heteroplasmic
m.13513G > A (p. D393N, ND5) mutation in the mito-
chondrial ND5 gene. The second patient had mitochon-
drial myopathy with 59 % heteroplasmic m.5591G > A
(tRNAAla), Table 2.
G. Carrier status
Carrier status for Mendelian recessive disorders was de-
tected in nine patients. Two patients had sickle cell trait,
two had β-thalassemia trait, one had CFTR gene muta-
tion (cystic fibrosis heterozygosity), and four females had
G6PD gene mutations (glucose-6-phosphatase dehydro-
genase heterozygosity).
H. Medically actionable genetic variants
Medically actionable genetic variants unrelated to the
clinical phenotype were identified in eight patients.
Seven patients had mutations in the G6PD gene
(c.563C > T in five patients, c.1003G > A in one patient,
andc.634A > G in one patient) and one had mutation in
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the MYBPC3 gene (c.2148 + 1G > A) that causes dilated
cardiomyopathy.
Discussion
In this study, WES provided useful clinical information
in most patients in whom several other tests were not
revealing. It attained a diagnostic rate of 50 % compared
with25–42%in other studies [6–11]. This higher yield is
a result of the frequent autosomal recessive diseases
(mostly homozygous mutations) in the region and the
multiple affected children in the same family.
Thirty-one of the 43 (72 %) patients with confirmed
molecular diagnoses had autosomal recessive disorders
compared with 34 % in another study [8]. Twenty-nine
of these patients were homozygous for the rare allele, in-
dicating consanguinity played a major role in making
autosomal recessive disorders frequent in this culture.
Of the patients with autosomal dominant disorders,
66 % had de novo mutations (Table 1 and Table 3). In
addition, all patients with X-linked disorders had de
novo mutations (Table 1A and Tables 2, 3). WES
detected a low-level mosaicism in one patient with X-
linked de novo variant in CDKL5, which was consistent
with his phenotype (Table 1). WES identified a mutation
in G6PC causing GSD1a (Table 1) in a patient who was
clinically suspected to have GSD III or IX due to cardio-
myopathy and hepatic manifestations but had normal
leukocyte enzymes for GSD III and IX. Establishing
GSD1a diagnosis in this patient enabled appropriate
counseling and genetic screening of the family members.
WES was especially helpful in a few patients with sus-
pected mitochondrial disorders in whom extensive mito-
chondrial work-up was not revealing. Mutations in
FBXL4 and C10orf2 causing mitochondrial DNA deple-
tion syndrome were identified (Table 2). WES facilitated
a rapid diagnosis in these patients with mitochondrial
disorders, avoiding a need for invasive muscle or skin
biopsies.
WES also provided a relatively rapid diagnosis in pa-
tients with treatable conditions, such as glycogen storage
diseases (Table 1B). In addition, it provided a diagnosis
in patients with atypical features of rare diseases, such as
the patient with global developmental delay, repetitive
hand movements, and brain atrophy without the molar
tooth sign. This patient was confirmed to have Joubert
syndrome due to a homozygous mutation in AHI1,
c.1051C > T (p.R351X) (Table 3). In addition, WES re-
vealed pathological variants in ARID1B in two patients
(Table 3); one of them was suspected to have mucopoly-
saccridosis. Founder mutations were identified in this
tribal population, such as the pathologic variant causing
transaldolase deficiency (Table 1). This finding facilitated
further diagnoses in our community using single gene
sequencing.
It is important to note that the results of WES should
be appraised carefully. In one patient, WES reported
a deleterious hemizygous mutation in SLC35A2,
c.617_620del (p.Q206fs),congenital disorder of glyco-
sylation, TYPE IIm (CDG2M). However, glycosylation
screening was normal in this patient and three
healthy brothers had the same mutation (not listed in
the table). In another patient, WES reported a patho-
genic mutation in MCCC2, c.1015G > A (p.V339M),
but urine organic acids were normal and the patient
had Sandhoff disease (confirmed by enzyme studies),
Table 1.
In most cases, extensive and expensive investigations
(including biochemical, genetic, and segregation studies)
were necessary after the results of WES to determine the
pathogenicity of the variants. In UAE, most families are
consanguineous and have multiple affected individuals.
Therefore, it was somewhat possible to stratify many of
the variants of unknown significance as pathogenic vs
non-pathogenic. Nevertheless, challenges remain in the
interpretation of the 12 likely pathogenic variants
(Table 1b). The availabilities of functional studies, im-
proved knowledge of rare allele frequencies of healthy
individuals, and more routine use of WES will improve
the yield of this powerful analytical tool.
Competent staff is needed to explain WES results and
to counsel patients and their families. The metabolic
centers should develop and adhere to appropriate guide-
lines for utilizing WES as a diagnostic tool. Position
statements and best practice guidelines are available
from the American college of Medical Genetics, Canadian
college of Medical Genetics and European society of
Human Genetics [12–14].
Many variants are confined to ethnic populations and
are, thus, difficult to diagnose by conventional genetic
methods [2, 15]. The cost of diagnosing genetic disor-
ders using conventional testing was estimated to be
about $25,000 per patient [4]. However, it is unknown
whether WES would increase or decrease this cost. In
this study, the cost of WES was covered by local insur-
ance companies for UAE citizens; the cost is a critical
issue for the majority of patients who are not citizens of
this country.
Conclusion
In this study, with the majority of patients had consan-
guineous families, WES identified pathogenic mutations
in 50 % of cases. WES also provided population-specific
information, which should facilitate molecular diagnosis
of metabolic and genetic disorders in the region. How-
ever, further studies, including cost-effective assessments
are needed before routine application of this test in IEM
and genetic clinics.
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